Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NQO2 | P16083 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31343779 | 0.86 | GAA (0.49) | GAAHTTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL20298364 | 0.85 | GAA (0.47) | GAAKDM4EHPGDSMN1; SMN2TSHR | |
| SCHEMBL23604250 | 0.85 | GAA (0.54) | GAAHTTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL25148646 | 0.85 | GAA (0.43) | GAAHTTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL30364696 | 0.85 | GAA (0.43) | GAAHTTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL22833387 | 0.84 | GAA (0.49) | GAAHTTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL20719772 | 0.83 | KEAP1 (0.49) | GAAHTTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL7395768 | 0.83 | GAA (0.54) | GAAHTTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL29069139 | 0.83 | GAA (0.42) | GAAHTTKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL14741034 | 0.82 | GAA (0.41) | GAAHTTKDM4EHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210386721-A1 | SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-12-16 | — | — | US | disclosed |
| WO-2020228649-A1 | SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386721-A1 | SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS | PDCD1, CD274, PDCD1LG2 | GAA 1465/4885HTT 3134/4885KDM4E 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.